Anupam Rasayan Q1 FY27 Revenue surges 36% YoY to ₹667.5 Crore; signs $300M deal
Anupam Rasayan reported Q1 FY27 consolidated revenue of ₹667.5 Crore, up 36% YoY. EBITDA increased 35% to ₹174.9 Crore. PAT grew 6% to ₹51.2 Crore. The company signed a Letter of Intent for a potential US$300 million revenue opportunity over ten years and is progressing with the Bliss GVS Pharma acquisition.
The substantial revenue growth, a large potential deal ($300 million), and progress on acquisition indicate a significant positive impact on the company's future prospects.
The company reported strong year-on-year growth in revenue and EBITDA, along with a significant potential long-term deal and progress in a strategic acquisition.
Anupam Rasayan India Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹667.5 Crore (Rs 6,675 Mn) for Q1FY27, marking a significant 36% year-on-year increase from ₹490.7 Crore (Rs 4,907 Mn) in Q1FY26.
EBITDA (including other income) for the quarter stood at ₹174.9 Crore (Rs 1,749 Mn), up 35% YoY from ₹129.2 Crore (Rs 1,292 Mn) in the same period last year. The EBITDA margin was maintained at 26.2% for Q1FY27. Profit After Tax (PAT) saw a 6% rise, reaching ₹51.2 Crore (Rs 512 Mn) in Q1FY27 compared to ₹48.5 Crore (Rs 485 Mn) in Q1FY26.
Commenting on the performance, Mr. Anand Desai, Managing Director, highlighted the strong start to fiscal year 2027, driven by sustained momentum and strategic execution. A key technological milestone achieved was the commercialization of Ethyl Trifluoroacetate (ETFA) using flow chemistry, strengthening the company's fluorination capabilities. Furthermore, Anupam Rasayan signed a Letter of Intent with BASQUEVOLT, S.A. for a potential long-term supply of a specialty chemical product, representing a revenue opportunity of approximately US$300 million spread over ten years.
The proposed acquisition of Bliss GVS Pharma is progressing as planned, and upon completion, it is expected to enhance the pharmaceutical platform through synergies in CDMO capabilities, product development, customer relationships, and access to regulated markets. The company remains confident in its growth prospects, supported by a strong product pipeline, expanding opportunities in Performance Materials and Pharmaceuticals segments, deeper customer engagement, and continued investment in technology and innovation.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.